Blogs

Categories

Select a sub-category to view results

Icon
Films and Coatings
vail 4ml
Pharmaceutical Packaging Components
Icon
Prefillable Systems
Icon
Self Injection Devices
Icon
Vial Containment Solutions
Icon
Washing and Sterilization
Icon
Reconstitution and Transfer Devices

Select a sub-category to view results

Icon
Analytical Lab Services
Icon
Contract Manufacturing
Icon
Fill-Finish
Icon
Regulatory Support

Select a sub-category to view results

Icon
Cell and Gene Therapy Packaging
Icon
Drug Development Process
Icon
Regulatory Challenges
Icon
Transitioning to Combination Products

Select a sub-category to view results

Icon
Corporate Development
Icon
ESG/Sustainability
Icon
One West Team (Employee Culture)
Icon
Our Culture of Giving (Philanthropy)
Icon
Research and Development

Previous Blogs

Two scientists in the lab

By Susan Dounce, PhD

February 20, 2019

Neovascular diseases of the eye are often chronic conditions treated with repeated intravitreal anti-VEGF injections. Although anti-VEGF therapies are preventing blindness, there are unique risks to intravitreal drug delivery that are exacerbated by the injection frequency. In particular, there is clinical evidence to suggest that some complications of these injections, though rare, might be tied to injection of particulate matter such as silicone oil, protein aggregates and foreign particulates.1,2